Kaletra

Active ingredient
Liponavir/r in Kombination mit einem Integrase-Inhibitor
Pharma Company
AbbVie Deutschland GmbH & Co. KG
Total Number of Doctors1
49 doctors
Total Number of Patients2
1,225 patients
Total minimum fees planned3
457,500.00 €

Observational Studies including Kaletra

Drug No. of doctors1 No. of patients2 Payment per patient3
Alle zur Hepatitis-C Behandlung zugelassenen direkt wirkende antiviralen Substanzen: z.B.: Sovaldi und Olysio, Viekirax, Incivo, Victrelis, Daclinza, Harvoni, Kaletra, Exviera n/a 325 600.00 €
Kaletra 21 300 75.00 € pro vollständiger Dokumentation (1 Bogen)
Kaletra 28 600 400.00 € pro Erfassungsjahr und komplette korrekte Dokumentation der Daten eines antiretroviral-oder PI-naiven Patienten

Background

Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.